CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

On June21, 2018, Catalyst Biosciences, Inc. (the “Company”) delivered a presentation at the JMP Securities 2018 Life Sciences Conference in New York, New York. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

(d) Exhibits

CATALYST BIOSCIENCES, INC. Exhibit
EX-99.1 2 d796994dex991.htm EX-99.1 EX-99.1 21 June 2018 Catalyst Biosciences Essential Medicines for Hemophilia Greater Convenience Superior Outcomes Exhibit 99.1 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements,…
To view the full exhibit click here

About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.